Roumen Balabanov to Prospective Studies
This is a "connection" page, showing publications Roumen Balabanov has written about Prospective Studies.
Connection Strength
0.034
-
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study. CNS Drugs. 2022 09; 36(9):977-993.
Score: 0.034